Characterization of tirzepatide-treated patients achieving different glycemic control levels in SURPASS-AP-Combo.

Bao Y, Han L, Du L, Ji L

Obesity (Silver Spring, Md.)1 Jun 2024

PMID38803303DOI10.1002/oby.24030PepBankPUB-38803303

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialSafety outcome
In Asia-Pacific adults with type 2 diabetes treated with tirzepatide, the incidence of hypoglycemic events was low.
In plain wordsIn Asia-Pacific adults with type 2 diabetes on tirzepatide, low blood sugar events were uncommon.
Peptide
Tirzepatide
Outcome
Not applicableHypoglycemic events incidence
Study
n = 598
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 40 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide treatment was well tolerated irrespective of the HbA1c level achieved, with a low incidence of hypoglycemic events.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of the SURPASS AP-Combo study.
Summary · context
Five hundred ninety-eight patients on tirzepatide treatment without rescue medication were included (56.9% male; mean age: 53.1 years; mean baseline HbA1c: 8.7% [71.6 mmol/mol]).
Report a problemFND-3880330312
02HumanObservational studyEfficacy outcome
In Asia-Pacific adults with type 2 diabetes on tirzepatide, those reaching HbA1c below 7.0% had greater HbA1c improvements at week 40 than those not reaching it.
In plain wordsAmong tirzepatide-treated adults with type 2 diabetes, those who reached HbA1c below 7.0% had larger HbA1c improvements than those who did not.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c improvement, achievers of HbA1c <7.0% versus non-achievers
Study
n = 598
Comparator
Patients achieving HbA1c 7.0% or higher at week 40
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 40 weeksAs given in this study (human).
Source sentences
Summary
Patients achieving HbA1c <7.0% (<53 mmol/mol) versus ≥7.0% (≥53 mmol/mol) were slightly younger with a shorter disease duration and lower HbA1c at baseline, and they had greater improvements in HbA1c, fasting serum glucose, body weight, BMI, waist circumference, waist-height ratio, diastolic blood p…
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of the SURPASS AP-Combo study.
Summary · context
Five hundred ninety-eight patients on tirzepatide treatment without rescue medication were included (56.9% male; mean age: 53.1 years; mean baseline HbA1c: 8.7% [71.6 mmol/mol]).
Report a problemFND-3880330301
03HumanObservational studyEfficacy outcome
In Asia-Pacific adults with type 2 diabetes on tirzepatide, those reaching HbA1c below 7.0% had greater improvements in fasting serum glucose at week 40 than those not reaching it.
In plain wordsAmong tirzepatide-treated adults with type 2 diabetes, those who reached HbA1c below 7.0% had larger fasting blood sugar improvements.
Peptide
Tirzepatide
Outcome
DecreaseFasting serum glucose improvement, achievers versus non-achievers
Study
n = 598
Comparator
Patients achieving HbA1c 7.0% or higher at week 40
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 40 weeksAs given in this study (human).
Source sentences
Summary
Patients achieving HbA1c <7.0% (<53 mmol/mol) versus ≥7.0% (≥53 mmol/mol) were slightly younger with a shorter disease duration and lower HbA1c at baseline, and they had greater improvements in HbA1c, fasting serum glucose, body weight, BMI, waist circumference, waist-height ratio, diastolic blood p…
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of the SURPASS AP-Combo study.
Summary · context
Five hundred ninety-eight patients on tirzepatide treatment without rescue medication were included (56.9% male; mean age: 53.1 years; mean baseline HbA1c: 8.7% [71.6 mmol/mol]).
Report a problemFND-3880330302
04HumanObservational studyEfficacy outcome
In Asia-Pacific adults with type 2 diabetes on tirzepatide, those reaching HbA1c below 7.0% had greater improvements in body weight at week 40 than those not reaching it.
In plain wordsAmong tirzepatide-treated adults with type 2 diabetes, those who reached HbA1c below 7.0% had larger body weight improvements.
Peptide
Tirzepatide
Outcome
DecreaseBody weight improvement, achievers versus non-achievers
Study
n = 598
Comparator
Patients achieving HbA1c 7.0% or higher at week 40
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 40 weeksAs given in this study (human).
Source sentences
Summary
Patients achieving HbA1c <7.0% (<53 mmol/mol) versus ≥7.0% (≥53 mmol/mol) were slightly younger with a shorter disease duration and lower HbA1c at baseline, and they had greater improvements in HbA1c, fasting serum glucose, body weight, BMI, waist circumference, waist-height ratio, diastolic blood p…
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of the SURPASS AP-Combo study.
Summary · context
Five hundred ninety-eight patients on tirzepatide treatment without rescue medication were included (56.9% male; mean age: 53.1 years; mean baseline HbA1c: 8.7% [71.6 mmol/mol]).
Report a problemFND-3880330303
05HumanObservational studyEfficacy outcome
In Asia-Pacific adults with type 2 diabetes on tirzepatide, those reaching HbA1c below 7.0% had greater improvements in BMI at week 40 than those not reaching it.
In plain wordsAmong tirzepatide-treated adults with type 2 diabetes, those who reached HbA1c below 7.0% had larger BMI improvements.
Peptide
Tirzepatide
Outcome
DecreaseBMI improvement, achievers versus non-achievers
Study
n = 598
Comparator
Patients achieving HbA1c 7.0% or higher at week 40
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 40 weeksAs given in this study (human).
Source sentences
Summary
Patients achieving HbA1c <7.0% (<53 mmol/mol) versus ≥7.0% (≥53 mmol/mol) were slightly younger with a shorter disease duration and lower HbA1c at baseline, and they had greater improvements in HbA1c, fasting serum glucose, body weight, BMI, waist circumference, waist-height ratio, diastolic blood p…
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of the SURPASS AP-Combo study.
Summary · context
Five hundred ninety-eight patients on tirzepatide treatment without rescue medication were included (56.9% male; mean age: 53.1 years; mean baseline HbA1c: 8.7% [71.6 mmol/mol]).
Report a problemFND-3880330304
06HumanObservational studyEfficacy outcome
In Asia-Pacific adults with type 2 diabetes on tirzepatide, those reaching HbA1c below 7.0% had greater improvements in waist circumference at week 40 than those not reaching it.
In plain wordsAmong tirzepatide-treated adults with type 2 diabetes, those who reached HbA1c below 7.0% had larger waist circumference improvements.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference improvement, achievers versus non-achievers
Study
n = 598
Comparator
Patients achieving HbA1c 7.0% or higher at week 40
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 40 weeksAs given in this study (human).
Source sentences
Summary
Patients achieving HbA1c <7.0% (<53 mmol/mol) versus ≥7.0% (≥53 mmol/mol) were slightly younger with a shorter disease duration and lower HbA1c at baseline, and they had greater improvements in HbA1c, fasting serum glucose, body weight, BMI, waist circumference, waist-height ratio, diastolic blood p…
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of the SURPASS AP-Combo study.
Summary · context
Five hundred ninety-eight patients on tirzepatide treatment without rescue medication were included (56.9% male; mean age: 53.1 years; mean baseline HbA1c: 8.7% [71.6 mmol/mol]).
Report a problemFND-3880330305
07HumanObservational studyEfficacy outcome
In Asia-Pacific adults with type 2 diabetes on tirzepatide, those reaching HbA1c below 7.0% had greater improvements in waist-height ratio at week 40 than those not reaching it.
In plain wordsAmong tirzepatide-treated adults with type 2 diabetes, those who reached HbA1c below 7.0% had larger waist-height ratio improvements.
Peptide
Tirzepatide
Outcome
DecreaseWaist-height ratio improvement, achievers versus non-achievers
Study
n = 598
Comparator
Patients achieving HbA1c 7.0% or higher at week 40
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 40 weeksAs given in this study (human).
Source sentences
Summary
Patients achieving HbA1c <7.0% (<53 mmol/mol) versus ≥7.0% (≥53 mmol/mol) were slightly younger with a shorter disease duration and lower HbA1c at baseline, and they had greater improvements in HbA1c, fasting serum glucose, body weight, BMI, waist circumference, waist-height ratio, diastolic blood p…
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of the SURPASS AP-Combo study.
Summary · context
Five hundred ninety-eight patients on tirzepatide treatment without rescue medication were included (56.9% male; mean age: 53.1 years; mean baseline HbA1c: 8.7% [71.6 mmol/mol]).
Report a problemFND-3880330306
08HumanObservational studyEfficacy outcome
In Asia-Pacific adults with type 2 diabetes on tirzepatide, those reaching HbA1c below 7.0% had greater improvements in diastolic blood pressure at week 40 than those not reaching it.
In plain wordsAmong tirzepatide-treated adults with type 2 diabetes, those who reached HbA1c below 7.0% had larger diastolic blood pressure improvements.
Peptide
Tirzepatide
Outcome
DecreaseDiastolic blood pressure improvement, achievers versus non-achievers
Study
n = 598
Comparator
Patients achieving HbA1c 7.0% or higher at week 40
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 40 weeksAs given in this study (human).
Source sentences
Summary
Patients achieving HbA1c <7.0% (<53 mmol/mol) versus ≥7.0% (≥53 mmol/mol) were slightly younger with a shorter disease duration and lower HbA1c at baseline, and they had greater improvements in HbA1c, fasting serum glucose, body weight, BMI, waist circumference, waist-height ratio, diastolic blood p…
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of the SURPASS AP-Combo study.
Summary · context
Five hundred ninety-eight patients on tirzepatide treatment without rescue medication were included (56.9% male; mean age: 53.1 years; mean baseline HbA1c: 8.7% [71.6 mmol/mol]).
Report a problemFND-3880330307
09HumanObservational studyEfficacy outcome
In Asia-Pacific adults with type 2 diabetes on tirzepatide, those reaching HbA1c below 7.0% had greater improvements in lipids at week 40 than those not reaching it.
In plain wordsAmong tirzepatide-treated adults with type 2 diabetes, those who reached HbA1c below 7.0% had larger blood lipid improvements.
Peptide
Tirzepatide
Outcome
MixedLipid improvement, achievers versus non-achievers
Study
n = 598
Comparator
Patients achieving HbA1c 7.0% or higher at week 40
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 40 weeksAs given in this study (human).
Source sentences
Summary
Patients achieving HbA1c <7.0% (<53 mmol/mol) versus ≥7.0% (≥53 mmol/mol) were slightly younger with a shorter disease duration and lower HbA1c at baseline, and they had greater improvements in HbA1c, fasting serum glucose, body weight, BMI, waist circumference, waist-height ratio, diastolic blood p…
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of the SURPASS AP-Combo study.
Summary · context
Five hundred ninety-eight patients on tirzepatide treatment without rescue medication were included (56.9% male; mean age: 53.1 years; mean baseline HbA1c: 8.7% [71.6 mmol/mol]).
Report a problemFND-3880330308
10HumanObservational studyEfficacy outcome
In Asia-Pacific adults with type 2 diabetes on tirzepatide, those reaching HbA1c below 7.0% had greater improvements in self-monitored blood glucose at week 40 than those not reaching it.
In plain wordsAmong tirzepatide-treated adults with type 2 diabetes, those who reached HbA1c below 7.0% had larger improvements in home blood glucose readings.
Peptide
Tirzepatide
Outcome
DecreaseSelf-monitored blood glucose improvement, achievers versus non-achievers
Study
n = 598
Comparator
Patients achieving HbA1c 7.0% or higher at week 40
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 40 weeksAs given in this study (human).
Source sentences
Summary
Patients achieving HbA1c <7.0% (<53 mmol/mol) versus ≥7.0% (≥53 mmol/mol) were slightly younger with a shorter disease duration and lower HbA1c at baseline, and they had greater improvements in HbA1c, fasting serum glucose, body weight, BMI, waist circumference, waist-height ratio, diastolic blood p…
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of the SURPASS AP-Combo study.
Summary · context
Five hundred ninety-eight patients on tirzepatide treatment without rescue medication were included (56.9% male; mean age: 53.1 years; mean baseline HbA1c: 8.7% [71.6 mmol/mol]).
Report a problemFND-3880330309
11HumanObservational studySafety outcome
In Asia-Pacific adults with type 2 diabetes, tirzepatide treatment was well tolerated irrespective of the HbA1c level achieved.
In plain wordsIn Asia-Pacific adults with type 2 diabetes, tirzepatide was well tolerated whatever HbA1c level people reached.
Peptide
Tirzepatide
Outcome
No significant changeTolerability irrespective of HbA1c level achieved
Study
n = 598
Comparator
Patients achieving HbA1c 7.0% or higher at week 40
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 40 weeksAs given in this study (human).
Source sentences
Summary
Tirzepatide treatment was well tolerated irrespective of the HbA1c level achieved, with a low incidence of hypoglycemic events.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of the SURPASS AP-Combo study.
Summary · context
Five hundred ninety-eight patients on tirzepatide treatment without rescue medication were included (56.9% male; mean age: 53.1 years; mean baseline HbA1c: 8.7% [71.6 mmol/mol]).
Report a problemFND-3880330311
12HumanObservational studyEfficacy outcome
In Asia-Pacific adults with type 2 diabetes on tirzepatide, those reaching HbA1c below 5.7% had further improvements in metabolic markers than those reaching 5.7% to 6.5% or above 6.5% to below 7.0%.
In plain wordsAmong tirzepatide-treated adults with type 2 diabetes, those reaching the lowest HbA1c group had larger improvements in metabolic markers.
Peptide
Tirzepatide
Outcome
MixedMetabolic markers, HbA1c <5.7% subgroup versus 5.7% to <7.0% subgroups
Study
n: not reported in source
Comparator
Patients achieving HbA1c 5.7% to 6.5% and >6.5% to <7.0%
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 40 weeksAs given in this study (human).
Source sentences
Summary
Patients achieving HbA1c 6.5% to 48 to <53 mmol/mol) were much younger, had much lower HbA1c, and had further improvements in metabolic markers.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post hoc analysis of the SURPASS AP-Combo study.
Summary · context
Five hundred ninety-eight patients on tirzepatide treatment without rescue medication were included (56.9% male; mean age: 53.1 years; mean baseline HbA1c: 8.7% [71.6 mmol/mol]).
Report a problemFND-3880330310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.